The FDA has approved the CustomVue monovision lasik device from AMO/Visx Inc. of Santa Clara, Calif. The product is designed to fully correct nearsightedness in the patient’s dominant eye but only partially correct it in the nondominant one, allowing patients to view both nearby and distant objects after an adjustment period. In contrast to traditional lasik, the procedure may reduce the need for patients over the age of 40 to wear reading glasses.